Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $37.90 Average Price Target from Analysts

Revance Therapeutics, Inc. (NASDAQ:RVNCGet Rating) has been given a consensus rating of “Moderate Buy” by the eleven brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $37.90.

A number of research analysts recently weighed in on the company. HC Wainwright lifted their target price on Revance Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a report on Friday, September 9th. The Goldman Sachs Group initiated coverage on Revance Therapeutics in a research report on Thursday, September 22nd. They issued a “buy” rating and a $33.00 price objective on the stock. Barclays raised their price objective on Revance Therapeutics from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Wednesday, November 16th. Cowen raised their price objective on Revance Therapeutics from $55.00 to $65.00 in a research report on Thursday, September 8th. Finally, Guggenheim raised their price objective on Revance Therapeutics to $36.00 in a research report on Tuesday, November 15th.

Revance Therapeutics Price Performance

Shares of Revance Therapeutics stock opened at $22.62 on Friday. Revance Therapeutics has a twelve month low of $11.27 and a twelve month high of $30.95. The stock has a market capitalization of $1.86 billion, a P/E ratio of -5.77 and a beta of 0.55. The company has a current ratio of 5.56, a quick ratio of 5.33 and a debt-to-equity ratio of 2.60. The business’s fifty day moving average price is $24.87 and its 200 day moving average price is $19.36.

Insider Activity at Revance Therapeutics

In related news, SVP Dwight Moxie sold 11,000 shares of the business’s stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $27.07, for a total value of $297,770.00. Following the completion of the sale, the senior vice president now directly owns 31,694 shares of the company’s stock, valued at $857,956.58. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 5.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Revance Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Mark Sheptoff Financial Planning LLC acquired a new position in Revance Therapeutics in the third quarter valued at approximately $54,000. Advisor Group Holdings Inc. boosted its stake in Revance Therapeutics by 60.6% in the first quarter. Advisor Group Holdings Inc. now owns 2,838 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 1,071 shares during the period. Princeton Global Asset Management LLC acquired a new position in shares of Revance Therapeutics during the third quarter worth approximately $68,000. Point72 Hong Kong Ltd acquired a new position in shares of Revance Therapeutics during the second quarter worth approximately $92,000. Finally, Prospera Financial Services Inc acquired a new position in shares of Revance Therapeutics during the first quarter worth approximately $122,000. 77.08% of the stock is currently owned by institutional investors and hedge funds.

About Revance Therapeutics

(Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Recommended Stories

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.